NLS Pharmaceutics AG

NASDAQ NLSP
$1.96 -0.03 -1.51%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 16.25 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
5.82M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
4.16M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
2.76M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-7.11 %

Upcoming events NLS Pharmaceutics AG

All events
No upcoming events scheduled

Stock chart NLS Pharmaceutics AG

Stock analysis NLS Pharmaceutics AG

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-2.85 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
4.14 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-2.31 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.92 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-145.08 -50.00

Price change NLS Pharmaceutics AG per year

1.30$ 6.04$
Min Max

Summary analysis NLS Pharmaceutics AG

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure NLS Pharmaceutics AG

Revenue and net income NLS Pharmaceutics AG

All parameters

About company NLS Pharmaceutics AG

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Address:
The Circle 6, Zurich, Switzerland, 8058
Company name: NLS Pharmaceutics AG
Issuer ticker: NLSP
ISIN: CH0523961370
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2021-01-29
Sector: Healthcare
Industry: Biotechnology
Site: https://nlspharma.com